| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E L Dovedov, M Iu Monako. [Effect of the tetrapeptide tuftsin on activity of the monoaminergic system of the brain in experimental pathology]. Voprosy meditsinskoi khimii. vol 41. issue 5. 1996-02-22. PMID:8553620. |
the peptide appeared to activate synaptic transfer in the dopaminergic nerve endings and to contribute to balance restoration in the neurotransmitter systems (particularly in the neostriatum) impaired by abnormalities. |
1996-02-22 |
2023-08-12 |
rat |
| W N Sloot, J B Gramsberge. Detection of salicylate and its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue. Journal of neuroscience methods. vol 60. issue 1-2. 1996-02-14. PMID:8544473. |
in conclusion, the described technique can be applied to study in vivo hydroxyl radical formation in direct relation with dopaminergic and serotonergic neurotransmitter changes during neurotoxic processes. |
1996-02-14 |
2023-08-12 |
rat |
| W Rostène, A Sarrieau, A Nicot, V Scarceriaux, C Betancur, D Gully, M Meaney, W Rowe, R De Kloet, D Pelapra. Steroid effects on brain functions: an example of the action of glucocorticoids on central dopaminergic and neurotensinergic systems. Journal of psychiatry & neuroscience : JPN. vol 20. issue 5. 1996-01-29. PMID:8527421. |
one such neurotransmitter is neurotensin, a neuropeptide which was reported to be closely related to central dopaminergic system regulation. |
1996-01-29 |
2023-08-12 |
rat |
| Y Miura, T Watanabe, T Noshiro, K Shimizu, T Kusakari, H Akama, S Shibukawa, W Miura, T Ohzeki, M Takahash. Plasma free dopamine: physiological variability and pathophysiological significance. Hypertension research : official journal of the Japanese Society of Hypertension. vol 18 Suppl 1. 1996-01-26. PMID:8529077. |
the results suggest that da is not only a precursor of norepinephrine biosynthesis but also plays an inherent role as an active neurotransmitter in the peripheral sympathoadrenal system, and that pda is a sensitive marker of peripheral dopaminergic activity, which may operate to modulate the cardiovascular and endocrine functions and participate in the pathogenesis of some types of hypertension. |
1996-01-26 |
2023-08-12 |
human |
| W E Kaufmann, S Naidu, S Budde. Abnormal expression of microtubule-associated protein 2 (MAP-2) in neocortex in Rett syndrome. Neuropediatrics. vol 26. issue 2. 1995-10-30. PMID:7566447. |
considering that map-2 expression is regulated by several neurotransmitter systems in adult cerebral cortex, particularly dopaminergic and cholinergic afferents that are deficient in rs, these neurochemical alterations could be related to this anomalous map-2 expression. |
1995-10-30 |
2023-08-12 |
Not clear |
| V Coiro, R Volpi, L Capretti, R Colla, G Caffarri, P P Vescovi, P Chioder. Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men. European journal of clinical investigation. vol 25. issue 6. 1995-10-05. PMID:7656919. |
in order to verify whether similar neurotransmitter alterations also affect the regulation of posterior pituitary hormone secretion, the arginine-vasopressin (avp) responses to the dopaminergic agonist apomorphine and in a different occasion to physostigmine, an acetylcholinesterase inhibitor, were evaluated in normal (n = 10) and type i diabetics (n = 16). |
1995-10-05 |
2023-08-12 |
human |
| S Shigetomi, S Fukuch. Recent aspect of the role of peripheral dopamine and its receptors in the pathogenesis of hypertension. Fukushima journal of medical science. vol 40. issue 2. 1995-09-21. PMID:7642168. |
dopamine is an essential and indispensable catecholamine, which acts not only as a neurotransmitter in dopaminergic and noradrenergic sympathetic neurons but also as an autocrine/paracrine substance in non-neuronal tissues. |
1995-09-21 |
2023-08-12 |
rat |
| D A Cory-Slecht. Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. Annual review of pharmacology and toxicology. vol 35. 1995-08-01. PMID:7598500. |
relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. |
1995-08-01 |
2023-08-12 |
Not clear |
| F J Seidler, S W Temple, E C McCook, T A Slotki. Cocaine inhibits central noradrenergic and dopaminergic activity during the critical developmental period in which catecholamines influence cell development. Brain research. Developmental brain research. vol 85. issue 1. 1995-07-14. PMID:7781166. |
brain development in the neonatal rat corresponds to fetal stages in man, and thus the transient ability of cocaine to interfere with noradrenergic and dopaminergic activity during the period in which differentiation is being patterned by neurotransmitter input, may be important in the neurobehavioral teratology of cocaine. |
1995-07-14 |
2023-08-12 |
rat |
| C M Miner, J R Davidso. Biological characterization of social phobia. European archives of psychiatry and clinical neuroscience. vol 244. issue 6. 1995-07-07. PMID:7772613. |
based on studies of neurotransmitter functions and pharmacologic response, the major neurotransmitter systems that have been implicated are the serotonergic, dopaminergic, and noradrenergic. |
1995-07-07 |
2023-08-12 |
Not clear |
| N Ogaw. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta medica Okayama. vol 49. issue 1. 1995-06-28. PMID:7762403. |
in the fields of psychiatry and neurology, the dopaminergic system is one of the most important neurotransmitter systems in the brain. |
1995-06-28 |
2023-08-12 |
Not clear |
| M Hansenne, W Pitchot, A Gonzalez Moreno, P Papart, M Timsit-Berthier, M Anssea. Catecholaminergic function and P300 amplitude in major depressive disorder (P300 and catecholamines). Electroencephalography and clinical neurophysiology. vol 96. issue 2. 1995-05-04. PMID:7535224. |
p300 amplitude appears to be modulated by multiple neurotransmitter systems, especially dopaminergic, noradrenergic as well as cholinergic and gabaergic. |
1995-05-04 |
2023-08-12 |
human |
| D J Sirinathsinghji, R Schuligoi, R P Heavens, A Dixon, S D Iversen, R G Hil. Temporal changes in the messenger RNA levels of cellular immediate early genes and neurotransmitter/receptor genes in the rat neostriatum and substantia nigra after acute treatment with eticlopride, a dopamine D2 receptor antagonist. Neuroscience. vol 62. issue 2. 1995-02-17. PMID:7830888. |
the cellular immediate early genes are involved in the transcriptional events associated with the dopaminergic regulation of neurotransmitter expression within neurons of the neostriatum. |
1995-02-17 |
2023-08-12 |
rat |
| J Kornhuber, M Welle. [Current status of biochemical hypotheses in the pathogenesis of schizophrenia]. Der Nervenarzt. vol 65. issue 11. 1995-02-09. PMID:7816150. |
the main focus of interest has shifted in recent years from the classical dopamine hypothesis to an increasing set of various neurotransmitter imbalance models of schizophrenic psychoses involving not only the dopaminergic system but also glutamatergic, serotonergic, cholinergic, gabaergic or peptidergic neuron systems. |
1995-02-09 |
2023-08-12 |
human |
| Iu A Skrinskaia, E M Nikulin. [The effect of deprenil on the dopaminergic system of the brain in mice of different genotypes during aging]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. vol 44. issue 4-5. 1995-01-27. PMID:7810226. |
effects of aging on brain dopaminergic system, e.g., neurotransmitter metabolism and different kinds of dopamine-dependent behaviour, were studied in mice of three inbred strains. |
1995-01-27 |
2023-08-12 |
mouse |
| K W Lange, P Riederer, M B Youdi. Biochemical actions of l-deprenyl (selegiline). Clinical pharmacology and therapeutics. vol 56. issue 6 Pt 2. 1995-01-18. PMID:7995015. |
because parkinson's disease is characterized by a decrease in dopaminergic neurotransmission in the basal ganglia, the selective inhibition of mao-b should lead to diminished metabolism of dopamine in the nigrostriatal system and a significant increase in the concentration of the neurotransmitter. |
1995-01-18 |
2023-08-12 |
human |
| F Issa, G A Gerhardt, J J Bartko, R L Suddath, M Lynch, P H Gamache, R Freedman, R J Wyatt, D G Kirc. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Psychiatry research. vol 52. issue 3. 1995-01-09. PMID:7991718. |
this approach enabled the study of the interactions of several metabolites of each of the three major neurotransmitter pathways (dopaminergic, noradrenergic, and serotonergic) to test existing hypotheses regarding the neurobiochemical basis of schizophrenia. |
1995-01-09 |
2023-08-12 |
human |
| D G Cole, J H Growdo. Therapy for progressive supranuclear palsy: past and future. Journal of neural transmission. Supplementum. vol 42. 1994-12-22. PMID:7964693. |
neurotransmitter replacement strategies targeting the dopaminergic, cholinergic, and serotonergic systems have been unsuccessful. |
1994-12-22 |
2023-08-12 |
Not clear |
| N Khan, A Antonini, D Parkes, M J Dahlitz, K Meier-Ewert, A Weindl, K L Leender. Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride. Neurology. vol 44. issue 11. 1994-12-20. PMID:7969966. |
there was no evidence of involvement of the striatal d2 dopaminergic neurotransmitter system in the basic pathophysiology of the narcoleptic syndrome despite an age-related increase in putaminal 11c-raclopride uptake. |
1994-12-20 |
2023-08-12 |
human |
| M J Aminof. Treatment of Parkinson's disease. The Western journal of medicine. vol 161. issue 3. 1994-12-15. PMID:7975571. |
other therapeutic strategies are being explored, including the use of type b monoamine oxidase inhibitors to reduce the metabolic breakdown of dopamine, catechol-o-methyltransferase inhibitors to retard the breakdown of levodopa, norepinephrine precursors to compensate for deficiency of this neurotransmitter, glutamate antagonists to counteract the effects of the subthalamic nucleus, and various neurotrophic factors to influence dopaminergic nigrostriatal cells. |
1994-12-15 |
2023-08-12 |
Not clear |